You are here: Industry Insights > EC

News List

A Brief Discussion on Roxadustat in the Midst of the Controversy zhulikou431
August 31, 2021
Recently, there is a good news for roxadustat, which is in the midst of the controversy. On August 19, 2021 local time, Astellas Pharma Inc. and FibroGen jointly announced that roxadustat was approved by the European Commission (EC) for adult patients.
Higher Coffee Consumption Tied to Lower Risk for Endometrial Cancer drugs.com
January 28, 2022
Increased coffee intake is associated with a lower risk for endometrial cancer (EC), according...
Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis drugs.com
January 19, 2022
Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory...
European Commission approves cystic fibrosis treatment for six to 11-year-olds pharmatimes
January 11, 2022
There is currently no cure for cystic fibrosis (CF), a debilitating, progressive condition with over 10,830 people in the UK currently diagnosed with the disease.
EC expands indication for Gilead’s Veklury to treat Covid-19 patients Pharmaceutical-Technology
December 23, 2021
The European Commission (EC) has granted approval to the Conditional Marketing Authorization (CMA) variation for Gilead Sciences’ antiviral Veklury (remdesivir) to include adult Covid-19 patients...
European Commission approves Pfizer’s atopic dermatitis treatment PharmaTimes
December 14, 2021
The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients.
EC approve Zeposia® to treat ulcerative colitis EuropeanPharmaceuticalReview
November 29, 2021
The European Commission (EC) has has granted a marketing authorisation for Zeposia® (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC)...
EC to procure 60 million doses of Valneva’s Covid-19 vaccine Pharmaceutical-Technology
November 12, 2021
The European Commission (EC) has approved an agreement to purchase up to 60 million doses of the Valneva inactivated vaccine candidate VLA2001 for Covid-19 over a period of two years.
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients pharmatimes
August 03, 2021
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...
Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval pharmatimes
July 22, 2021
Myovant Sciences and Gedeon Richter have gained an approval from the European Commission (EC) for its uterine fibroids treatment Ryeqo, the company announced 20th.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page